(Q53907124)

22 May 2018

title

Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. (English)

1 reference

22 May 2018

0 references

1 reference

1 reference

W Ondo

1

1 reference

22 May 2018

C Hunter

2

1 reference

22 May 2018

K D Vuong

3

1 reference

22 May 2018

K Schwartz

4

1 reference

22 May 2018

J Jankovic

5

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 July 2000

1 reference

22 May 2018

published in

Movement Disorders

1 reference

22 May 2018

volume

15

1 reference

22 May 2018

issue

4

1 reference

22 May 2018

page(s)

678-682

1 reference

22 May 2018

Essential tremor: clinical correlates in 350 patients

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

How common is the most common adult movement disorder? estimates of the prevalence of essential tremor throughout the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Prevalence of essential tremor: a door-to-door survey in Terrasini, Sicily. Sicilian Neuro-Epidemiologic Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Differences in the prevalence of essential tremor among elderly African Americans, whites, and Hispanics in northern Manhattan, NY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Mapping of a familial essential tremor gene, FET1, to chromosome 3q13

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Red nuclear and cerebellar but no olivary activation associated with essential tremor: A positron emission tomoraphic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

A positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

The effect of ethanol on alcohol-responsive essential tremor: a positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

The effect of gabapentin on neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Effectiveness of gabapentin in controlling spasticity: a quantitative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Gabapentin for relief of spasticity associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Double-blind controlled trial of gabapentin in essential tremor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Variability in amplitude of untreated essential tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Diurnal variation of essential and physiological tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Assessing tremor severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

A summary of mechanistic hypotheses of gabapentin pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

Effective treatment of orthostatic tremor with gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200007%2915%3A4%3C678%3A%3AAID-MDS1012%3E3.0.CO%3B2-0

10.1002/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0

21 January 2018

Identifiers

DOI

1 reference

22 May 2018

PubMed ID

10928578

1 reference

22 May 2018